These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36062490)

  • 1. Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment:
    Yildiz Pekoz A; Akbal Dagistan O; Fael H; Culha M; Erturk A; Basarir NS; Sahin G; Serhatli M; Cakirca G; Tekin S; Sen LS; Sevim M; Mulazimoglu Durmusoglu L; Yegen BC
    Drug Deliv; 2022 Dec; 29(1):2846-2854. PubMed ID: 36062490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral therapy for COVID-19: Derivation of optimal strategy based on past antiviral and favipiravir experiences.
    Shiraki K; Sato N; Sakai K; Matsumoto S; Kaszynski RH; Takemoto M
    Pharmacol Ther; 2022 Jul; 235():108121. PubMed ID: 35121001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favipiravir in SARS-CoV-2 Infection: Is it Worth it?
    Batiha GE; Moubarak M; Shaheen HM; Zakariya AM; Usman IM; Rauf A; Adhikari A; Dey A; Alexiou A; Hetta HF; Al-Gareeb AI; Al-Kuraishy HM
    Comb Chem High Throughput Screen; 2022; 25(14):2413-2428. PubMed ID: 35430987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates.
    Marlin R; Desjardins D; Contreras V; Lingas G; Solas C; Roques P; Naninck T; Pascal Q; Behillil S; Maisonnasse P; Lemaitre J; Kahlaoui N; Delache B; Pizzorno A; Nougairede A; Ludot C; Terrier O; Dereuddre-Bosquet N; Relouzat F; Chapon C; Ho Tsong Fang R; van der Werf S; Rosa Calatrava M; Malvy D; de Lamballerie X; Guedj J; Le Grand R
    Nat Commun; 2022 Aug; 13(1):5108. PubMed ID: 36042198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.
    Driouich JS; Cochin M; Lingas G; Moureau G; Touret F; Petit PR; Piorkowski G; Barthélémy K; Laprie C; Coutard B; Guedj J; de Lamballerie X; Solas C; Nougairède A
    Nat Commun; 2021 Mar; 12(1):1735. PubMed ID: 33741945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination.
    Padhi AK; Dandapat J; Saudagar P; Uversky VN; Tripathi T
    FEBS Lett; 2021 Sep; 595(18):2366-2382. PubMed ID: 34409597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review on favipiravir: the properties, function, and usefulness to treat COVID-19.
    Hashemian SM; Farhadi T; Velayati AA
    Expert Rev Anti Infect Ther; 2021 Aug; 19(8):1029-1037. PubMed ID: 33372567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model.
    Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J
    EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New anti-viral drugs for the treatment of COVID-19 instead of favipiravir.
    Aktaş A; Tüzün B; Aslan R; Sayin K; Ataseven H
    J Biomol Struct Dyn; 2021 Nov; 39(18):7263-7273. PubMed ID: 32783586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
    Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
    Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favipiravir use for SARS CoV-2 infection.
    Boretti A
    Pharmacol Rep; 2020 Dec; 72(6):1542-1552. PubMed ID: 33108587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Favipiravir in the Battle with Respiratory Viruses.
    Smyk JM; Majewska A
    Mini Rev Med Chem; 2022; 22(17):2224-2236. PubMed ID: 35184710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favipiravir for the treatment of COVID-19 in elderly patients-what do we know after 2 years of COVID-19?
    Papp H; Lanszki Z; Keserű GM; Jakab F
    Geroscience; 2022 Jun; 44(3):1263-1268. PubMed ID: 35543795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
    Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel property of hexokinase inhibition by Favipiravir and proposed advantages over Molnupiravir and 2 Deoxy D glucose in treating COVID-19.
    Kulkarni P; Padmanabhan S
    Biotechnol Lett; 2022 Jul; 44(7):831-843. PubMed ID: 35608787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
    Tsuji M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescence of ocular surface in a Covid -19 patient after Favipiravir treatment: a case report.
    Doran MA; Aytogan H; Ayıntap E
    Virol J; 2021 Jul; 18(1):146. PubMed ID: 34256791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial.
    Udwadia ZF; Singh P; Barkate H; Patil S; Rangwala S; Pendse A; Kadam J; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Feb; 103():62-71. PubMed ID: 33212256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.